NCT00002049 is a NA clinical trial of Thymopentin in HIV Infections, sponsored by Immunobiology Research Institute.

Who is sponsoring NCT00002049?

NCT00002049 is sponsored by Immunobiology Research Institute.

What drugs are being tested in NCT00002049?

Interventions in NCT00002049: Thymopentin.

What condition does NCT00002049 study?

NCT00002049 studies HIV Infections.

Is NCT00002049 still recruiting?

NCT00002049 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00002049

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Completed NA Last updated 23 June 2005

What this trial tests

NA trial testing Thymopentin in HIV Infections. Completed.

Quick facts

Lead sponsor	Immunobiology Research Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Masking	double
Primary purpose	treatment
Sites	1 location across United States

Drugs / interventions tested

Thymopentin (THYMOPENTIN) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Immunobiology Research Institute

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with HIV who do not yet have AIDS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002049 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunobiology Research Institute
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing